Human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma

Presse Medicale

Volumn 43, Issue 12, 2014, Pages e429-e434

  Dalianis, Tina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; WART VIRUS VACCINE;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CHEMORADIOTHERAPY; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG SAFETY; EPIDEMIC; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTERNATIONAL COOPERATION; NONHUMAN; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; SEXUAL INTERCOURSE; SHORT SURVEY; SMOKING; TONGUE CARCINOMA; TONSIL CARCINOMA; TREATMENT RESPONSE; VIRUS DETECTION; WART VIRUS; COMPLICATION; FEMALE; HEAD AND NECK TUMOR; MALE; OROPHARYNX TUMOR; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; VIROLOGY; VIRUS CELL TRANSFORMATION;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, VIRAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SQUAMOUS CELL CARCINOMA OF HEAD AND NECK;

EID: 84923019306     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.08.010     Document Type: Short Survey

References (50)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Licitra L., Bernier J., Grandi C., Merlano M., Bruzzi P., Lefebvre J.L. Cancer of the oropharynx. Crit Rev Oncol Hematol 2002, 41:107-122.
3. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720.
4. Mellin H., Friesland S., Lewensohn R., Dalianis T., Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000, 89:300-304.
5. Dahlstrand H.M., Dalianis T. Presence and influence of human papillomaviruses (HPV) in Tonsillar cancer. Adv Cancer Res 2005, 93:59-89.
6. Ramqvist T., Dalianis T. Oropharyngeal epidemic and human papillomavirus. Emerg Infect Dis 2010, 16:1671-1677.
7. WHO IARC Monographs on the evaluation of carcinogenic risk to humans 2007, International Agency for Research on Cancer, Lyon, France.
8. Gillison M.L., Chaturvedi A.K., Lowy D.R. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113:3036-3046.
9. Chesson H.W., Ekwueme D.U., Saraiya M., Markowitz L.E. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008, 14:244-251.
10. Tommasino M. The human papillomavirus family and carcinogenesis. Sem in Cancer Biol 2014, 26:13-21.
11. Zur Hausen H. Papillomavirus infections: a major cause of human cancer. Infections causing human cancer 2006, 145-243. Wiley-VCH Verlag, Weinheim.
12. de Roda Husman A.M., Walboomers J.M., van den Brule A.J., Meijer C.J., Snijders P.J. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995, 76:1057-1062.
13. Tieben L.M., ter Schegget J., Minnaar R.P., Bouwes Bavinck J.N., Berkhout R.J., Vermeer B.J., et al. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 1993, 42:265-279.
14. van den Brule A.J., Pol R., Fransen-Daalmeijer N., Schouls L.M., Meijer C.J., Snijders P.J. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002, 40:779-787.
15. Clavel C., Masure M., Bory J.P., Putaud I., Mangeonjean C., Lorenzato M., et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999, 80:1306-1311.
16. Gravitt P.E., Peyton C.L., Apple R.J., Wheeler C.M. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998, 36:3020-3027.
17. Schmitt M., Bravo I.G., Snijders P.J., Gissmann L., Pawlita M., Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006, 44:504-512.
18. Lindquist D., Romanitan M., Hammarstedt L., Nasman A., Dahlstrand H., Lindholm J., et al. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 2007, 1:350-355.
19. Smeets S.J., Hesselink A.T., Speel E.J., Haesevoets A., Snijders P.J., Pawlita M., et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007, 121:2465-2472.
20. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005, 32:S59-S66.
21. Sturgis E.M., Cinciripini P.M. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?. Cancer 2007, 110:1429-1435.
22. Hammarstedt L., Lindquist D., Dahlstrand H., Romanitan M., Dahlgren L.O., Joneberg J., et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006, 119:2620-2623.
23. Marur S., D'Souza G., Westra W.H., Forastiere A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010, 11:781-789.
24. Nasman A., Attner P., Hammarstedt L., Du J., Eriksson M., Giraud G., et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?. Int J Cancer 2009, 125:362-366.
25. Attner P., Du J., Nasman A., Hammarstedt L., Ramqvist T., Lindholm J., et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 2010, 12612:2879-2884.
26. Braakhuis B.J., Visser O., Leemans C.R. Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol 2009, 45:e85-e89.
27. Conway D.I., Stockton D.L., Warnakulasuriya K.A., Ogden G., Macpherson L.M. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999)-recent trends and regional variation. Oral Oncol 2006, 42:586-592.
28. Robinson K.L., Macfarlane G.J. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing?. Oral Oncol 2003, 39:31-36.
29. Hammarstedt L., Dahlstrand H., Lindquist D., Onelöv L., Ryott M., Luo J., et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol 2007, 1279:988-992.
30. Chaturvedi A.K., Engels E.A., Anderson W.F., Gillison M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008, 26:612-619.
31. Mellin H., Dahlgren L., Munck-Wikland E., Lindholm J., Rabbani H., Kalantari M., et al. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 2002, 102:152-158.
32. Koskinen W.J., Chen R.W., Leivo I., Makitie A., Back L., Kontio R., et al. Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer 2003, 107:401-406.
33. Mellin Dahlstrand H., Lindquist D., Bjornestal L., Ohlsson A., Dalianis T., Munck-Wikland E., et al. P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res 2005, 25:4375-4383.
34. Mellin H., Friesland S., Auer G., Dalianis T., Munck-Wikland E. Human papillomavirus and DNA ploidy in tonsillar cancer-correlation to prognosis. Anticancer Res 2003, 23:2821-2828.
35. Dahlgren L., Mellin H., Wangsa D., Heselmeyer-Haddad K., Björnestål L., Lindholm J., et al. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer 2003, 107:244-249.
36. Ang K.K., Harris J., Wheeler R., Weber R., Rosenthal D.I., Nguyen-Tan P.F., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
37. Marklund L., Näsman A., Ramqvist T., Dalianis T., Munck-Wikland E., Hammarstedt L. Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. Cancer Med 2012, 1:82-88.
38. Anaya-Saavedra G., Ramirez-Amador V., Irigoyen-Camacho M.E., Garcia-Cuellar C.M., Guido-Jimenez M., Mendez-Martinez R., et al. High association of human papillomavirus infection with oral cancer: a case-control study. Arch Med Res 2008, 39:189-197.
39. D'Souza G., Agrawal Y., Halpern J., Bodison S., Gillison M.L. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009, 199:1263-1269.
40. Syrjänen S., Puranen M. Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med 2000, 11:259-274.
41. Näsman A., Nordfors C., Grün N., Munck-Wikland E., Ramqvist T., Marklund L., et al. Absent/low CD44 intensity and positive HPV status in oropharyngeal squamous cell carcinoma indicates a very high survival. Cancer Med 2013, 2:507-1842.
42. Näsman A., Andersson E., Marklund L., Tertipis N., Hammarstedt-Nordenwall L., Nyberg T., et al. HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome. PloS One 2013, 8:e7702543.
43. + Tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer 2013, 49:2522-2530.
44. Spanos W.C., Nowicki P., Lee D.W., Hoover A., Hostager B., Gupta A., et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009, 135:1137-1146.
45. Kreimer A.R., Bhatia R.K., Messeguer A.L., Gonzalez P., Herrero R., Giuliano A.R. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010, 37:386-391.
46. Rautava J., Syrjanen S. Human papillomavirus infections in the oral mucosa. J Am Dent Assoc 2011, 142:905-914.
47. Du J., Nordfors C., Ahrlund-Richter A., Sobkowiak M., Romanitan M., Näsman A., et al. Prevalence of oral human papillomavirus infection among youth, Sweden. Emerg Infect Dis 2012, 18:1468-1471.
48. Nordfors C., Grün N., Haeggblom L., Tertipis N., Sivars L., Mattebo M., et al. Oral human papillomavirus prevalence in high school students of one municipality in Sweden. Scand J Infect Dis 2013, 45:878-881.
49. Steinau M., Hariri S., Gillison M.L., Broutian T.R., Dunne E.F., Tong Z.Y., et al. Prevalence of cervical and oral human papillomavirus infections among US women. J Infect Dis 2014, 209:1739-1743.
50. Nordfors C., Vlastos A., Du J., Ährlund-Richter A., Tertipis N., Grün N., et al. Human papillomavirus prevalence is high in oral samples of patients with tonsillar and base of tongue cancer. Oral Oncol 2014, 50:491-497.